期刊
CURRENT OPINION IN NEUROBIOLOGY
卷 63, 期 -, 页码 122-130出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.conb.2020.04.001
关键词
-
资金
- Agence Nationale de la Recherche [ANR-15-IDEX-02 NeuroCoG, ANR-18-CE16-0009-01 AXYON, ANR-18-CE16-002203 HDEV, ANR-18-CE13-002-9-04 TELOPOST]
- AGEMED program from INSERM
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (AdG grant) [834317]
- Association Huntington France
- FRM [FDT201904008035]
- European Research Council (ERC) [834317] Funding Source: European Research Council (ERC)
- Agence Nationale de la Recherche (ANR) [ANR-18-CE16-0009] Funding Source: Agence Nationale de la Recherche (ANR)
Over the past twenty years there have been numerous advances in our understanding of Huntington's disease (HD) and other neurodegenerative proteopathies such as Alzheimer's disease and Parkinson's disease. In each case, disease-specific proteins are expressed and accumulate; what has been less clear is precisely what problems are caused by the accumulation. Recently we have begun to appreciate that increased protein levels or changes in the ratios of different isoforms affect the movement of molecules along the axon, thereby disrupting neuronal function. Huntingtin, the protein involved in HD, plays a special role in axonal transport, and very recent studies have found that its activity - and the movement of its cargoes - is altered not only in HD but in other neurological diseases. Here, we contextualize these studies and consider how modulating huntingtin activity could provide new avenues to therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据